10 High Growth High Margin Stocks to Buy Now

7. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Operating Margin (TTM): 38.76%

5-Year Revenue Growth Rate: 21.61%

Number of Hedge Fund Holders: 61

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow the success established by the company’s cystic fibrosis (CF) operation. The firm emphasized that Vertex’s CF therapies continue to rake in significant cash flows, which could allow for future commercial development.

Barclays expects Vertex’s IgAN (immunoglobulin A nephropathy) program to yield encouraging results early this year, adding that the renal franchise’s prospects continue to be “underappreciated” by the market.

Barclays also mentioned Journavx, claiming that the increase in prescriptions and revenues in 2026 has lately been “overlooked” by the market.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.